BIO (BIO) news

BIO-RAD LABORATORIES, INC. <BIO.N>: JEFFERIES RAISES TARGET PRICE TO $335 FROM $315

South Korea's AI Mania Spills Into Crypto, With Worldcoin as Top Pick

RootData: BIO will unlock tokens worth about $1 million in one week

Bio-Rad’s Schwartz reports 34.69% voting stake in Sartorius AG after inheritance event

Bitget Spot Cross Margin adds BIO/USDT

Bio Protocol launches AI research hub to challenge grant gatekeepers

According to documents submitted to the SEC, biotechnology company Avai Bio Inc and Ainnova Tech have agreed, as of May 7, 2026, to jointly terminate their previously established joint venture and related licensing agreements.

CoreWeave reviews its Q1 2026 performance: 1. Secured AI labs, hyperscalers, and enterprise-level clients

BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.

BIO (BioProtocol) fluctuates 61.1% in 24 hours: driven by BioXP upgrade activation and Upbit trading volume surge

BIO (BioProtocol) fluctuates 66.1% in 24 hours: Driven by BioXP upgrade and PEPTAIIgnitionSale

BIO (BioProtocol) fluctuates 41.0% in 24 hours: Driven by PEPTAIIgnitionSale oversubscription and trading volume surge

BIO (BioProtocol) sees 41.2% volatility in 24 hours: High-volume rebound driven by Upbit listing and network upgrade

BIO (BioProtocol) fluctuates 43.7% in 24 hours: Surge in trading volume and synergy with DeSci sector drive movement

BioProtocol (BIO) fluctuates 42.5% in 24 hours: EliLilly acquisition news and whale purchases drive rebound

Bio Protocol launches BioXP upgrade, Ignition sale now open

BIO (BioProtocol) fluctuates 42.0% in 24 hours, price rebound driven by Upbit listing and network upgrade

BIO (BioProtocol) fluctuates 42.0% within 24 hours, trading volume surges by $139 million driving a 23.1% rebound

Kashiv Biosciences has agreed to be acquired by Amneal Pharmaceuticals, aiming to create a fully integrated global leader in biosimilars.

BIO (BioProtocol) 24-hour volatility at 40.4%: Downward wedge breakout and volume surge drive movement

BIO (BioProtocol) fluctuated by 63.3% in 24 hours: BioXPSeason2 launch and DeSci narrative revival drive

After breaking the main cost line, BIO has doubled! Will ORDI be next?

BIO briefly reached 0.039 USDT, with a 24-hour increase of 95.35%

BIO (BioProtocol) fluctuated 82.3% in 24 hours (high at $0.035): Trading volume surges over 600%, driving price rebound

BIO (BioProtocol) 24-hour volatility at 45.7%: Trading volume surges 715% driving price swings

BIO (BioProtocol) fluctuates 42.0% in 24 hours: Surge in trading volume by 340% drives price rebound

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Climb Bio (stock code: CLYM) announced today that the U.S. Food and Drug Administration (FDA) has granted its candidate drug Budoprutug Fast Track designation for the treatment of primary membranous nephropathy.

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)